Jun
2026
Shanghai New International Expo Center
Visit us
stand E6F61, Pharma Ingredients

Zennova Pharmaceuticals (chengdu) co., Ltd

About Us

Zennova Pharmaceuticals Group is an international pharmaceutical company , driven by innovative research and development. We have excellent product development technology and world-class quality products. We provide world-class medicines of superior value to our patients. Our strategy focuses on global research and development, manufacturing in China, and serving global markets.  We focus on four major therapeutic areas: ophthalmology, virology, cardiovascular and oncology. We currently have R&D and production facilities in New York, New Jersey, and Chengdu, China. Our State-of-The-Art pharmaceutical manufacturing facility located in Chengdu Tianfu International Biotown is designed to qualify US FDA, EU EMA, and China cGMP standards. It is set up to meet world-class  quality standard for all dosage forms of medicines. It includes various oncology drugs, sterile eye drops products, central nervous system medicines, and other complex formulation drugs. Our products are to be sold to the US, Europe, China and other global markets.

  • Country/Region:
    China
  • Founded:
    2018
  • On CPHI since:
    2025
  • Certificates:
    1
  • Employees:
    50 - 99
Company types
Biopharmaceutical company
CMO/CDMO
Contract Research Organisation (CRO)
Distributor/Import Export
Generics/Biosimilars Manufacturer
Primary activities
Chemical Development
Contract Manufacturer
Contract Research Organisation
Pharmaceutical Company (generic finished products)
Contact info
  • No. 617, Fenghuang Road,, Shuangliu District,, 610200, Chengdu, Sichuan, China
Event information
CPHI & PMEC China 2026
  • 16 Jun 2026 - 18 Jun 2026
  • Shanghai New International Expo Center
  • Visit us at stand E6F61, Pharma Ingredients

Products Featured at CPHI & PMEC China 2026

  • Pramipexole Hydrochloride

    Product Pramipexole Hydrochloride

    Pramipexole dihydrochloride is a non-ergot dopamine agonist indicated for the treatment of:

    • Parkinson's disease (PD)

    Moderate-to-severe primary Restless Legs Syndrome (RLS)